Our findings provide novel insights into the regulatory mechanisms of YAP activity mediated by lncRNA-encoded small proteins, underscoring the therapeutic potential of YAPer-ORF-neutralizing antibodies in the treatment of developmental disorders and cancers characterized by dysregulated YAP activity. The gene discussed is YAP1; the disease is cancer.